Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Oct 20, 2022 6:57pm
170 Views
Post# 35037734

RE:RE:RE:Just a Friendly Reminder...

RE:RE:RE:Just a Friendly Reminder...Hahaha - ya I've got them all on ignore. 
It's been a treat kicking their nonsense to the curb.
Can just imagine how they are freaking out right now.

Fact is - there are no buyers out there.
Picked up 1000 at 56 and then another 1000 later at 54 today.

To Wriggles point - I'm betting on a lipid type nano-carrier for this advanced design.
That makes sense.
That just might send us via the lymphatic pathway, bypassing the liver on first pass.
Just what we'd want to see - for chronic.

Seems it is possible with H2S - just not sure if it can be accomplished with 346.
If it's possible - they've got it.

Also - to what degree might we avoid first pass?  Maybe there's some leakage.
How much could we reduce our drug dosing by in such a situation?

Tough times on the markets but I'm hoping the science is even stronger now !!!!

This modified formulation explains so much ... my guesses only
IBD pushed out to see if it's using similar technology
352 may be obsolete now
Couldn't discuss fast-track if you didn't know if the new direction was going to be the winner.
I'm sure there's more !!!

----------------------------








<< Previous
Bullboard Posts
Next >>